Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Adaptimmune Therapeutics's enterprise value was $55.27M on Oct 19, 2026, against $79.45M a year earlier. Over the last 5 years it ranged from $9.31M to $3.65B, with a median of $846.49M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Oct 19, 2026 | $55.27M | +34.9% |
| 2025 | Dec 31, 2025 | $40.96M | -94.1% |
| 2024 | Dec 31, 2024 | $690.72M | -24.5% |
| 2023 | Dec 29, 2023 | $915.00M | -25.8% |
| 2022 | Dec 30, 2022 | $1.23B | -62.3% |
| 2021 | Dec 31, 2021 | $3.27B | -28.9% |
| 2020 | Dec 31, 2020 | $4.60B | +607.8% |
| 2019 | Dec 31, 2019 | $649.97M | -80.7% |
| 2018 | Dec 31, 2018 | $3.36B | -4.4% |
| 2017 | Dec 29, 2017 | $3.52B | +136.0% |
| 2016 | Dec 30, 2016 | $1.49B | -69.5% |
| 2015 | Dec 31, 2015 | $4.89B | – |
See a number that looks wrong?